Endometrial Cancer Diagnostics Market: Type of Condition (Endometrioid Carcinoma, Serous Adenocarcinoma, Adenosquamous Carcinoma, Carcinomasarcoma), Type of Test (Hysteroscopy,  Endometrial Biopsy, Dilation and Curettage, Ultrasound, CT Scan, MRI), End-user (Diagnostic Centers, Hospitals, Ambulatory Surgical Centers) and Geography 


Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Endometrial Cancer Diagnostics Market size was valued at USD 21.4 billion in 2021 and is expected to reach USD 28.4 billion by 2028, at a CAGR of 5.4% during the forecast period 2022-2028. Endometrial Cancer is the most common form of uterine cancer as the endometrium is part of the uterus. Endometrial cancer is often called uterine cancer. It is the most commonly diagnosed gynecologic cancer. Endometrial cancer forms when cells in the inner lining of the uterus (endometrium) begin to grow out of control. Unlike breast and prostate cancer where screening tests are available to the general population endometrial cancer is most commonly diagnosed at endometrial biopsy in symptomatic patients. No generally applicable screening test is available. Among all test types hysteroscopy is most commonly recommended uterine cancer diagnostic test. According to the American Cancer Society, in 2017, about 61380 new cases of uterine cancer were diagnosed and around 10,000 were dead.  According to WHO, developed regions such as North America and Europe registers greater incidence rate for endometrial cancer due to lifestyle changes adopted by women. Women with abnormal vaginal bleeding are detected with endometrial cancer at an early stage. Endometrial cancer is the sixth most common cancer in women worldwide, according to statistics. Because of the increased prevalence of Endometrial Cancer Diagnostics Market is predicted to grow significantly. Other key factors contributing to the market's growth include rising female obesity, increased menopausal hormone therapy, changes in sedentary lifestyle, socioeconomic factors, rising consumption of unhealthy diet, rising occurrence of Polycystic Ovarian Syndrome (PCOS), and rising prevalence of breast or ovarian tumour. Another condition that contributes to the development of endometrial cancer is diabetes. Endometrial cancer is four times more likely in diabetes women than in non-diabetic women, according to the American Cancer Society. Endometrial cancer is caused by such factors in women.

Endometrial Cancer Diagnostics Market Summary

Study Period


Base Year




Largest Market


Fastest Growing Market

Endometrial Cancer Diagnostics Market Dynamics Drivers And Restraints

Increase in the prevalence and incidence of endometrial cancer propels the growth of the endometrial cancer diagnostics market globally. As per the stats of American Cancer Society, in 2012, about 47,130 new cases of endometrial cases were diagnosed and 8010 women died because of it. Furthermore increase in awareness regarding uterine diseases, availability of various treatment options and early diagnostic options drives the growth of the globally. Moreover increase in healthcare expenditure, technological advancements and developments and advanced healthcare services also propels the market growth of endometrial cancer diagnostics globally. However, low accuracy rate in the results of diagnostic tests, high cost associated with the tests and treatments, adverse effects and lack of awareness about innovative technologies may hinder the growth of the globally.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Endometrial Cancer Diagnostics Market Segmentation

type of condition
  • Endometrioid Carcinoma
  • Serous Adenocarcinoma
  • Adenosquamous Carcinoma
  • Carcinomasarcoma
type of test
  • Hysteroscopy
  • Endometrial Biopsy
  • Dilation and Curettage
  • Ultrasound
  • CT Scan
  • MRI
End user
  • Diagnostic Centers
  • Hospitals
  • Ambulatory Surgical Centers


Frequently Asked Questions

The endometrial cancer diagnostics market is projected to expand at a CAGR of 5.4% during the forecast period  

Abbott Laboratories, Ariad Pharmaceuticals, Merck, Becton, Dickinson, Siemens Healthcare

North America is the fastest-growing region for endometrial cancer diagnostics market

  • Abbott Laboratories (U.S)
  • Ariad Pharmaceuticals, Inc. (U.S)
  • Merck & Co., Inc. (U.S)
  • Becton, Dickinson & Co. (U.S)
  • Siemens Healthcare Inc. (Germany)
  • Hoffman-La Roche Ltd. (Switzerland)
  • GlaxoSmithKline Plc., etc. (UK)